• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.用于卵巢癌的紫杉醇和卡铂(TC)方案
Hosp Pharm. 2014 May;49(5):425-31. doi: 10.1310/hpj4905-425.
2
Paclitaxel, Carboplatin, and trastuzumab.紫杉醇、卡铂和曲妥珠单抗。
Hosp Pharm. 2014 Nov;49(10):913-9. doi: 10.1310/hpj4910-913.
3
Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.卡铂和脂质体阿霉素用于治疗卵巢癌。
Hosp Pharm. 2016 Jun;51(6):442-9. doi: 10.1310/hpj5106-442.
4
Gemcitabine and Carboplatin (renally dosed) regimen for bladder cancer.吉西他滨和顺铂(根据肾功能给药)方案用于膀胱癌治疗。
Hosp Pharm. 2015 Feb;50(2):103-7. doi: 10.1310/hpj5002-103.
5
nab-Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer.纳米白蛋白结合型紫杉醇联合吉西他滨方案治疗胰腺癌
Hosp Pharm. 2014 Jan;49(1):18-22. doi: 10.1310/hpj4901-18.
6
Paclitaxel and trastuzumab for breast cancer.紫杉醇和曲妥珠单抗用于治疗乳腺癌。
Hosp Pharm. 2014 Apr;49(4):338-44. doi: 10.1310/hpj4904-338.
7
Nab-Paclitaxel and Carboplatin (Nab-PC) Regimen for Advanced Non-Small-Cell Lung Cancer.纳武单抗联合卡铂(Nab-PC)方案用于晚期非小细胞肺癌
Hosp Pharm. 2014 Oct;49(9):804-8. doi: 10.1310/hpj4909-804.
8
Carboplatin (renally dosed) and Etoposide regimen for small-cell lung cancer.卡铂(肾剂量给药)和依托泊苷方案用于小细胞肺癌。
Hosp Pharm. 2013 Apr;48(4):274-9. doi: 10.1310/hpj4804-274.
9
Gemcitabine and Vinorelbine (GemVin) Regimen.吉西他滨与长春瑞滨(吉西长春瑞滨)方案
Hosp Pharm. 2014 Jun;49(6):508-16. doi: 10.1310/hpj4906-508.
10
Cabazitaxel and Prednisone Regimen for Prostate Cancer.卡巴他赛与泼尼松联合方案用于前列腺癌治疗
Hosp Pharm. 2015 Jun;50(6):460-3. doi: 10.1310/hpj5006-460.

引用本文的文献

1
A Case of CUP with Malignant Pleural Effusion: Overcoming Diagnostic and Therapeutic Hurdles with Chemotherapy.一例伴有恶性胸腔积液的不明原发癌:化疗攻克诊断与治疗难题
Case Rep Oncol. 2024 Oct 21;17(1):1194-1200. doi: 10.1159/000540866. eCollection 2024 Jan-Dec.
2
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.帕博利珠单抗联合卡铂和紫杉醇作为复发性/转移性头颈部鳞状细胞癌的一线治疗(KEYNOTE-B10):一项单臂 IV 期试验。
J Clin Oncol. 2024 Sep 1;42(25):2989-2999. doi: 10.1200/JCO.23.02625. Epub 2024 Jul 22.
3
ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.ABCB1和ERCC1基因多态性与妇科癌症患者基于卡铂/紫杉醇化疗的肾毒性和肝毒性相关。
Eur J Clin Pharmacol. 2020 Oct;76(10):1401-1408. doi: 10.1007/s00228-020-02934-9. Epub 2020 Jun 20.

本文引用的文献

1
Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.采用 CKD-EPI 和 Cockcroft-Gault 公式并结合不同体重描述符计算低血清肌酐浓度肺癌患者的卡铂剂量。
Lung Cancer. 2013 Jan;79(1):54-8. doi: 10.1016/j.lungcan.2012.10.009. Epub 2012 Nov 4.
2
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.卵巢癌中诱导性吉西他滨或紫杉醇联合卡铂后行紫杉醇巩固治疗的 III 期临床试验。
Gynecol Oncol. 2011 Dec;123(3):479-85. doi: 10.1016/j.ygyno.2011.08.018. Epub 2011 Oct 5.
3
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.一项随机 III 期临床试验,比较 IV 卡铂和紫杉醇 × 3 疗程后观察与每周维持低剂量紫杉醇治疗早期卵巢癌患者的疗效:一项妇科肿瘤学组研究。
Gynecol Oncol. 2011 Jul;122(1):89-94. doi: 10.1016/j.ygyno.2011.03.013. Epub 2011 May 6.
4
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.晚期卵巢癌:顺铂-拓扑替康序贯治疗与卡铂-紫杉醇和卡铂-紫杉醇比较的 III 期随机研究。
J Natl Cancer Inst. 2010 Oct 20;102(20):1547-56. doi: 10.1093/jnci/djq362. Epub 2010 Oct 11.
5
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.卡铂联合紫杉醇加或不加吉西他滨一线治疗上皮性卵巢癌的 III 期临床试验。
J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.
6
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.聚乙二醇脂质体阿霉素和卡铂与紫杉醇和卡铂治疗铂敏感复发性晚期卵巢癌患者的比较。
J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24.
7
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?对于肾功能正常的超重和肥胖患者,卡铂给药剂量与体重有关吗?
Cancer Chemother Pharmacol. 2009 Jun;64(1):115-22. doi: 10.1007/s00280-008-0856-x. Epub 2008 Nov 7.
8
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.卡铂和紫杉醇对比顺铂、紫杉醇及多柔比星用于晚期卵巢癌一线化疗:一项希腊合作肿瘤学组(HeCOG)研究
Eur J Cancer. 2008 Oct;44(15):2169-77. doi: 10.1016/j.ejca.2008.06.035. Epub 2008 Aug 6.
9
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.一项关于伐司朴达(PSC 833)联合紫杉醇和卡铂与单纯紫杉醇和卡铂相比,用于治疗IV期或初次减瘤不完全的III期上皮性卵巢癌或原发性腹膜癌患者的III期研究。
J Clin Oncol. 2008 Jun 1;26(16):2674-82. doi: 10.1200/JCO.2007.14.9807.
10
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.白细胞生长因子使用建议的2006年更新:基于证据的临床实践指南
J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8.

用于卵巢癌的紫杉醇和卡铂(TC)方案

Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.

作者信息

Akin Julie M, Waddell J Aubrey, Solimando Dominic A

机构信息

Dr. Akin is a pharmacy practice (PGY1) resident at Blount Memorial Hospital , Maryville, Tennessee .

出版信息

Hosp Pharm. 2014 May;49(5):425-31. doi: 10.1310/hpj4905-425.

DOI:10.1310/hpj4905-425
PMID:24958952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4062714/
Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

摘要

癌症化疗的复杂性要求药剂师熟悉所使用的复杂治疗方案和高毒性药物。本专栏回顾了与抗肿瘤治疗的制备、调配和给药相关的各种问题,以及用于治疗恶性疾病的市售和研究性药物。有关主题的问题或建议请发送至小多米尼克·A·索利曼多,肿瘤药学服务公司总裁,弗吉尼亚州阿灵顿市威尔逊大道4201号#110 - 545,邮编22203,电子邮箱:OncRxSvc@comcast.net;或J·奥布里·沃德尔,田纳西大学药学院教授;布朗特纪念医院药学部肿瘤药剂师,田纳西州玛丽维尔市东拉马尔·亚历山大大道907号,邮编37804,电子邮箱:waddfour@charter.net。